



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Adress: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/528,806	06/14/2005	Jan Menne	37998-237159	6218
26694	7590	05/29/2008	EXAMINER	
VENABLE LLP P.O. BOX 34385 WASHINGTON, DC 20043-9998			WEN, SHARON X	
ART UNIT	PAPER NUMBER			
	1644			
MAIL DATE	DELIVERY MODE			
05/29/2008	PAPER			

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/528,806	Applicant(s) MENNE ET AL.
	Examiner SHARON WEN	Art Unit 1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 07 February 2008.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1,2,9-44 and 56-61 is/are pending in the application.
 4a) Of the above claim(s) 10-24,27,29,32-42,44 and 56-61 is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 1-2, 9, 25-26, 28, 30-31 and 43 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date: _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date: _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. Applicant's amendment, filed 02/07/2008, has been entered.

Claims 3-8 and 45-55 have been canceled.

Claims 1-2, 9-44 and 56-61 are pending.

Claims 10-24, 27, 29, 32-42, 44, 56-61 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 07/02/2007.

Claims 1-2, 9, 25-26, 28, 30-31 and 43 are currently under examination as they read on a method of treatment and/or prevention of cardiovascular diseases in patient comprising administering tocopherol as the elected species of inhibitor of PKC-alpha and beta.

2. This Action will be in response to Applicant's Arguments/Remarks, filed 02/07/2008.

The rejections of record can be found in the previous Office Action.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 1-2, 9, 25-26, 28, 30-31 and 43 are rejected under **35 U.S.C. 112, first paragraph**, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

There is insufficient written description of the genus encompassed by the recitation of "inhibitor of protein kinase C- α ". It is noted that Applicant elected tocopherol as the inhibitor; however the claims do not limit the inhibitor to tocopherol.

In response to Applicant's assertion that the instant specification provides sufficient written description for the "inhibitor", the following is noted.

The specification discloses the "inhibitor" means a substance which competitively inhibits the biological activity of protein kinase C- α , allosterically changes the spatial structure of PKC- α , or inhibits PKC- α by substrate inhibition (see page 6). However, there is no information regarding what structural features would likely be associated with such selective, inhibitory activity because the specification does not describe the complete structure, partial structures, physical properties, or chemical properties of the compounds that selectively inhibit PKC- α as commensurate by the claims. Thus, the specification does not disclose a correlation between selective inhibitory activity and structure of a putative inhibitor.

The level of the skill and knowledge in the art is such that there is no known correlation between any structural component and the ability to selectively inhibit PKC- α for the genus of inhibitor encompassed by the claims. Thus, the disclosure does not allow one of skill in the art to visualize or recognize the structure of any compound required to practice the claimed invention. Accordingly, one of skill in the art would conclude that Applicant would not have been in possession of the claimed composition comprising the compounds because the genus of compounds possessing the desired activity are not adequately described in the instant disclosure as-filed.

Applicant is invited to amend the claim to recite the elected species of inhibitor, i.e., tocopherol, to obviate this rejection.

The New Grounds of Written Description Rejection herein for the recitation of the "inhibitor" is necessitated by Applicant's amendment to the claims, filed 02/07/2008.

Art Unit: 1644

5. Claims 1-2, 9, 25-26, 28, 30-31 and 43 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Applicant's arguments, filed 02/07/2008, have been fully considered but have not been found convincing essentially for the reasons of record.

In response to Applicant's reliance on the PKC- α knock-out mouse model in Appendix A, submitted on 02/08/2008, it is noted that the enablement rejection is based upon the use tocopherol as the key/critical active agent in preventing cardiovascular diseases in patients because tocopherol was the elected species of inhibitor of PKC- α .

The PKC- α knockout model does not demonstrate using tocopherol as an inhibitor of PKC- α for preventing cardiovascular disease therefore, it is not commensurate with the scope of the claim.

Applicant's arguments have not been persuasive.

Therefore, the rejection of record is **maintained** for the reasons of record, as it applies to the amended and newly added claims. The rejection of record is incorporated by reference herein, as if reiterating in full.

Claim Rejections - 35 USC § 102

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

7. Claims 1-2, 9, 25-26, 28, 30-31 and 43 rejected under 35 U.S.C. 102(b) as being anticipated by Hennekens (U.S. Patent 5,871,766, reference of record).

Applicant's arguments, filed 02/07/2008, have been fully considered but have not been found convincing essentially for the reasons of record.

In response to Applicant's argument that the '766 patent does not teach inhibitor of PCK- α , it is noted that the prior art teaches a method of treating cardiovascular diseases comprising administration of **tocopherol** (e.g. see column 1, lines 20-25; column 2, lines 50-55; column 3, lines 50-53; column 4, lines 42-46; and claims 1 and 7). Give that tocopherol is an elected species of inhibitor of PCK- α , it would inherently possess features of inhibiting PCK- α especially in the absence of evidence to the contrary.

There is no requirement that a person of ordinary skill in the art would have recognized the inherent disclosure at the time of invention, but only that the subject matter is in fact inherent in the prior art reference. *Schering Corp. v. Geneva Pharm. Inc.*, 339 F.3d 1373, 1377, 67 USPQ2d 1664, 1668 (Fed. Cir. 2003).

Applicant's arguments have not been persuasive.

Therefore, the rejection of record is **maintained** for the reasons of record, as it applies to the amended and newly added claims. The rejection of record is incorporated by reference herein, as if reiterated in full.

Conclusion

8. No claim is allowed.
9. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHARON WEN whose telephone number is (571)270-3064. The examiner can normally be reached on Monday-Thursday, 8:30AM-6:00PM, ALT. Friday, EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Eileen O'Hara can be reached on (571)272-0878. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Sharon Wen, Ph.D./
Examiner, Art Unit 1644
May 22, 2008

/Eileen B. O'Hara/
Supervisory Patent Examiner
Art Unit 1644